Low-Dose IL-2 Fails to Preserve Beta-Cell Function in New-Onset Type 1 Diabetes
A rigorous phase 2b trial finds low-dose IL-2 robustly expands regulatory T cells but does not slow beta-cell loss in newly diagnosed type 1 diabetes.
Summary
The DIABIL-2 trial tested whether low-dose interleukin-2 (IL-2) — a cytokine that selectively boosts immune-suppressing regulatory T cells (Tregs) — could protect the insulin-producing beta cells that are destroyed in type 1 diabetes. In 141 participants aged 6–35 years, two dosing regimens of IL-2 were compared to placebo over 12 months. The drug successfully expanded Tregs as intended, peaking just five days after treatment began. Despite this clear biological effect, beta-cell function measured by C-peptide levels was no better in the IL-2 groups than in the placebo group. The therapy was safe and well tolerated across all ages. Researchers conclude the inflammatory environment at diabetes onset may be too intense for IL-2 monotherapy, pointing toward earlier intervention or combination immunotherapy approaches.
Detailed Summary
Type 1 diabetes is an autoimmune disease in which the immune system destroys insulin-producing beta cells in the pancreas. A key driver is a relative deficiency of regulatory T cells (Tregs), which normally keep immune attacks in check. Low-dose interleukin-2 (IL-2) had been shown to selectively expand Tregs, making it an appealing candidate to halt or slow beta-cell destruction early in the disease course.
The DIABIL-2 trial was a double-blind, placebo-controlled, phase 2b study conducted across 19 academic centers in five European countries. A total of 141 participants aged 6–35 years who had been diagnosed with type 1 diabetes for fewer than three months were randomized to one of two IL-2 dosing regimens — injections every two weeks or every week after an initial induction course — or to placebo. The primary outcome was preservation of residual beta-cell function, measured by C-peptide response during a standardized mixed-meal tolerance test at 12 months.
Despite a robust and statistically significant expansion of Tregs — peaking at day 5 of the induction phase — there was no significant difference in C-peptide area under the curve between the IL-2 and placebo groups at 12 months (geometric mean ratio 1.06, 95% CI 0.56–2.01; p=0.85). Results were consistent across both dosing regimens and in both children/adolescents and adults.
Safety data were reassuring. Serious adverse events occurred in 20% of placebo participants versus 10% in the IL-2 groups, with only one event per group deemed probably treatment-related. The favorable tolerability profile across all age groups is an important finding.
The authors interpret the null efficacy result as evidence that the intense inflammatory environment at clinical diabetes onset may overwhelm Treg-mediated suppression when IL-2 is used alone. They propose that future strategies should test IL-2 at the preclinical or pre-symptomatic stage, or in combination with other immunomodulatory agents. The confirmed biological activity of low-dose IL-2 keeps the mechanistic rationale alive for autoimmune and immunoaging research.
Key Findings
- Low-dose IL-2 did not preserve beta-cell function (C-peptide AUC) vs. placebo at 12 months (p=0.85).
- IL-2 produced robust Treg expansion peaking at day 5, confirming target engagement despite no clinical benefit.
- Serious adverse events were lower in the IL-2 group (10%) than placebo (20%), supporting a favorable safety profile.
- Results were consistent across children/adolescents and adults and across both weekly and biweekly dosing schedules.
- Authors recommend testing IL-2 earlier in disease course or combined with other immunotherapies.
Methodology
DIABIL-2 was a double-blind, randomized, placebo-controlled phase 2b trial in 141 participants aged 6–35 with newly diagnosed type 1 diabetes across 19 European centers. Participants were randomized 1:1:1 to biweekly IL-2 (regimen A), weekly IL-2 (regimen B), or placebo for 12 months, stratified by pubertal stage. The primary endpoint was change in C-peptide AUC from a mixed-meal tolerance test, analyzed in the intention-to-treat population.
Study Limitations
The summary is based on the abstract only, as the full paper is not open access. The trial enrolled participants within three months of diagnosis, meaning the beta-cell-destructive inflammatory response was already well established; earlier intervention might yield different results. C-peptide AUC is a surrogate endpoint and longer follow-up would be needed to assess impact on insulin requirements and hypoglycemia risk.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: